- Potential subjects must be at least 9 days past their last course of MT-3724 treatment and have recovered from any side effects attributed to MT-3724 to at least Common Terminology Criteria for Adverse Events (CTCAE, v. 4.03; Appendix 4) Grade 2 prior to initiating additional cycles of MT-3724 through this compassionate use protocol. Subjects with pre-existing AEs at screening that are severe or life threatening by CTCAE grading should not be enrolled.